Damora Therapeutics, Inc.

For the period ended Sep 30, 2026. Filed Nov 4, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2026 · Filed Nov 4, 2026

DMRA$24.07+1.6%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Changes in Shareholders’ Equity

(in thousands, except share amounts)

Mezzanine Equity · Shareholders’ Equity
Three Months Ended September 30, 2025 · Preferred Shares · Series B Non-Voting Convertible Preferred Shares · Series C Non-Voting Convertible Preferred Shares · Ordinary Shares · AdditionalPaid-In · Accumulated · AccumulatedOtherComprehensive · TotalShareholders’
Shares · Amount · Shares · Amount · Shares · Amount · Shares · Amount · Capital · Deficit · Income · Equity
Balance at June 30, 2025	159	$1,341		—	$—	—	$—	1,324,560	$—	292,297	$(283,494)	$809	$9,612
Stock-based compensation expense	—	—		—	—	—	—	—	—	164	—	—	164
Issuance of common stock in connection with vesting of restricted stock units	—	—		—	—	—	—	2,652	—	9	—	—	9
Other comprehensive income, net	—	—		—	—	—	—	—	—		—	14	14
Net loss	—	—		—	—	—	—	—	—	—	(3,133)	—	(3,133)
Balance at September 30, 2025	159	$1,341		—	$—	—	$—	1,327,212	$—	$292,470	$(286,627)	$823	$6,666
Mezzanine Equity · Shareholders’ Equity
Three Months Ended September 30, 2026	Preferred Shares		Series B Non-Voting Convertible Preferred Shares	Series C Non-Voting Convertible Preferred Shares	Ordinary Shares	AdditionalPaid-In	Accumulated	AccumulatedOtherComprehensive	TotalShareholders’
Shares · Amount · Shares · Amount · Shares · Amount · Shares · Amount · Capital · Deficit · Income (Loss) · Equity
Balance at June 30, 2026	—	$-		16,366	$117,621	1,722	$12,376	61,734,601	$1	$931,649	$(546,320)	$732	$516,059
Share-based compensation expense	—	—		—	—	—	—	—	—	7,541	—	—	7,541
Issuance of ordinary shares in connection with vesting of restricted share units	—	—		—	—	—	—	918	—	—	—	—	—
Exercise of options	—	—		—	—	—	—	1,800	—	54	—	—	54
Proceeds from At-the-Market facility, net of issuance costs of $226	—	—		—	—	—	—	167,423	—	5,063	—	—	5,063
Other comprehensive loss, net	—	—		—	—	—	—	—	—	—	—	(965)	(965)
Net loss	—	—		—	—	—	—	—	—	—	(31,991)	-	(31,991)
Balance at September 30, 2026	—	$—		16,366	$117,621	1,722	$12,376	61,904,742	$1	$944,307	$(578,311)	$(233)	$495,761

Mezzanine Equity · Shareholders’ Equity
Nine Months Ended September 30, 2025 · Preferred Shares · Series B Non-Voting Convertible Preferred Shares · Series C Non-Voting Convertible Preferred Shares · Ordinary Shares · AdditionalPaid-In · Accumulated · AccumulatedOtherComprehensive · TotalShareholders’
Shares · Amount · Shares · Amount · Shares · Amount · Shares · Amount · Capital · Deficit · Income · Equity
Balance at December 31, 2024	161	$1,360		—	$—	—	$—	1,316,989	$—	$291,898	$(277,524)	$97	$14,471
Stock-based compensation expense	—	—		—	—	—	—	—	—	515	—	—	515
Conversion of Series A Preferred Stock	(2)	(19)		—	—	—	—	2,201	—	19	—	—	19
Issuance of common stock in connection with vesting of restricted stock units	—	—		—	—	—	—	8,022	—	38	—	—	38
Other comprehensive income, net	—	—		—	—	—	—	—	—		—	726	726
Net loss	—	—		—	—	—	—	—	—	—	(9,103)	—	(9,103)
Balance at September 30, 2025	159	$1,341		—	$—	—	$—	1,327,212	$—	$292,470	$(286,627)	$823	$6,666
Mezzanine Equity · Shareholders’ Equity
Nine Months Ended September 30, 2026	Preferred Shares		Series B Non-Voting Convertible Preferred Shares	Series C Non-Voting Convertible Preferred Shares	Ordinary Shares	AdditionalPaid-In	Accumulated	AccumulatedOtherComprehensive	TotalShareholders’
Shares · Amount · Shares · Amount · Shares · Amount · Shares · Amount · Capital · Deficit · Income (Loss) · Equity
Balance at December 31, 2025	159	$1,341		16,366	$117,621	43,882	$297,291	1,597,321	$-	$310,688	$(487,363)	$802	$239,039
Share-based compensation expense	—	—		—	—	—	—	—	—	16,819	—	—	16,819
Conversion of Series A preferred shares to Ordinary Shares	(159)	(1,341)		—	—	—	—	158,361	—	1,341	—	—	1,341
Conversion of Series C Preferred Shares issued in connection with the asset acquisition of Damora Therapeutics, Inc.	—	—		—	—	(2,364)	(16,990)	2,364,000	—	16,990	—	—	—
Shareholder approval of the issuance of ordinary shares upon conversion of Series C Preferred Shares	—	—		—	—	(39,641)	(266,811)	39,641,000	1	266,810	—	—	—
Issuance of ordinary shares in connection with offering, net of issuance costs of $20,753	—	—		—	—	—	—	16,644,737	—	295,497	—	—	295,497
Forfeiture of shares	—	—		—	—	(155)	(1,114)	(9,638)	—	1,114	—	—	—
Issuance of ordinary shares in connection with vesting of restricted share units						—	—	6,936	—	—			—
Exercise of options	—	—		—	—	—	—	94,202	—	703	—	—	703
Other comprehensive loss, net	—	—		—	—	—	—	—	—	—	—	(1,035)	(1,035)
Proceeds from At-the-Market facility, net of issuance costs of $914	—	—		—	—	—	—	1,407,823	—	34,345	—	—	34,345
Net loss	—	—		—	—	—	—	—	—	—	(90,948)	—	(90,948)
Balance at September 30, 2026	—	$—		16,366	$117,621	1,722	$12,376	61,904,742	$1	$944,307	$(578,311)	$(233)	$495,761

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.